Cargando…

A systematic review of real-world evidence of the management of macular oedema secondary to branch retinal vein occlusion

This review assessed the real-world evidence of the management of macular oedema secondary to branch retinal vein occlusion (BRVO). A meta-analysis of 2530 eyes from 48 real-world studies of therapies for macular oedema secondary to BRVO was conducted. Baseline characteristics, visual, anatomical an...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ang, Juan Lyn, Ah-Moye, Sarah, Kim, Leah N., Nguyen, Vuong, Hunt, Adrian, Barthelmes, Daniel, Gillies, Mark C., Mehta, Hemal
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2020
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7608462/ https://www.ncbi.nlm.nih.gov/pubmed/32313172 http://dx.doi.org/10.1038/s41433-020-0861-9

Ejemplares similares

Changes in 12-month outcomes over time for age-related macular degeneration, diabetic macular oedema and retinal vein occlusion
por: Bhandari, Sanjeeb, et al.
Publicado: (2022)

12‐month outcomes of ranibizumab versus aflibercept for macular oedema in central retinal vein occlusion: data from the FRB! registry
por: Niedzwiecki, Mateusz, et al.
Publicado: (2021)

Perifoveal Microcirculation in Macular Oedema with Retinal Vein Occlusion
por: Noma, Hidetaka, et al.
Publicado: (2012)

Treatment of Branch Retinal Vein Occlusion induced Macular Edema with Bevacizumab
por: Abegg, Mathias, et al.
Publicado: (2008)

Clinical characteristics of branch retinal vein occlusion with increased retinal haemorrhage during treatment for macular oedema
por: Lee, You Hyun, et al.
Publicado: (2020)

Real-World Results of Switching Treatment from Ranibizumab to Aflibercept in Macular Oedema Secondary to Branch Retinal Vein Occlusion
por: Konidaris, Vasileios E., et al.
Publicado: (2018)

Real-World Evidence for Treat-and-Extend Regimen of Ranibizumab Therapy for Macular Oedema Secondary to Branch Retinal Vein Occlusion
por: Rodríguez-Fernández, Carmen Antía, et al.
Publicado: (2022)

Two-year outcomes of intravitreal bevacizumab therapy for macular oedema secondary to branch retinal vein occlusion
por: Hikichi, Taiichi, et al.
Publicado: (2014)

Initial observation or treatment for diabetic macular oedema with good visual acuity: two‐year outcomes comparison in routine clinical practice: data from the Fight Retinal Blindness! Registry
por: Gabrielle, Pierre‐Henry, et al.
Publicado: (2020)

Comment on: Ranibizumab and aflibercept intravitreal injection for treatment naïve and refractory macular oedema in branch retinal vein occlusion
por: Elkazza, Sumeia A, et al.
Publicado: (2020)

Treatments for macular oedema following central retinal vein occlusion: systematic review
por: Ford, John A, et al.
Publicado: (2014)

Indirect comparisons of ranibizumab and dexamethasone in macular oedema secondary to retinal vein occlusion
por: Thom, Howard HZ, et al.
Publicado: (2014)

Short-term and long-term results after intravitreal bevacizumab therapy for macular oedema in branch retinal vein occlusion
por: Pidro, Ajla, et al.
Publicado: (2022)

Characteristics of major and macular branch retinal vein occlusion
por: Choi, Yu-Jin, et al.
Publicado: (2022)

Neovascular age‐related macular degeneration: A review of findings from the real‐world Fight Retinal Blindness! registry
por: Nguyen, Vuong, et al.
Publicado: (2021)

Comparative efficacy and safety of approved treatments for macular oedema secondary to branch retinal vein occlusion: a network meta-analysis
por: Regnier, Stephane A, et al.
Publicado: (2015)

Anti-vascular endothelial growth factor dosing frequency and visual outcomes in macular oedema following branch retinal vein occlusion
por: Modi, Yasha S., et al.
Publicado: (2023)

Real-world outcomes of intravitreal bevacizumab treat-and-extend for cystoid macular oedema secondary to central retinal vein occlusion
por: Gildea, David, et al.
Publicado: (2023)

Real world evidence on 5661 patients treated for macular oedema secondary to branch retinal vein occlusion with intravitreal anti-vascular endothelial growth factor, intravitreal dexamethasone or macular laser
por: Gale, Richard, et al.
Publicado: (2021)

Factors correlated with the resolution of macular oedema after one dose injection of intravitreal triamcinolone acetonide treatment in branch retinal vein occlusion
por: Zhang, Shuang, et al.
Publicado: (2016)

Multiple extra macular branch retinal vein occlusions in hyperhomocysteinemia
por: Gore, Abhijit Diwakar, et al.
Publicado: (2014)

Cytokines and the Pathogenesis of Macular Edema in Branch Retinal Vein Occlusion
por: Noma, Hidetaka, et al.
Publicado: (2019)

Hemiretinal vein occlusion 12-month outcomes are unique with vascular endothelial growth factor inhibitors: data from the Fight Retinal Blindness! Registry
por: Hunt, Adrian Robert, et al.
Publicado: (2023)

Combination Therapy for Macular Oedema in Retinal Vein Occlusions: 3-Year Results from a Real-World Clinical Practice
por: Horner, Faye, et al.
Publicado: (2020)

Arteriovenous Sheathotomy for Persistent Macular Edema in Branch Retinal Vein Occlusion
por: Sohn, Joon Hong, et al.
Publicado: (2006)

Consecutive Macular Edema and Visual Outcome in Branch Retinal Vein Occlusion
por: Baek, Sung Uk, et al.
Publicado: (2014)

Foveal Sensitivity and Morphology in Major and Macular Branch Retinal Vein Occlusion
por: Noma, Hidetaka, et al.
Publicado: (2012)

Microaneurysms cause refractory macular edema in branch retinal vein occlusion
por: Tomiyasu, Taneto, et al.
Publicado: (2016)

Drug treatment of macular oedema secondary to central retinal vein occlusion: a network meta-analysis
por: Ford, John A, et al.
Publicado: (2014)

Dexamethasone Implant for Diabetic Macular Oedema: 1-Year Treatment Outcomes from the Fight Retinal Blindness! Registry
por: Bhandari, Sanjeeb, et al.
Publicado: (2022)

Edaravone (MCI-186) is effective as a free radical scavenger following arteriovenous sheathotomy for treatment of macular oedema associated with branch retinal vein occlusion
por: Maeno, T, et al.
Publicado: (2009)

Comparative Evaluation Between Ranibizumab Combined with Laser and Bevacizumab Combined with Laser Versus Laser Alone for Macular Oedema Secondary to Branch Retinal Vein Occlusion
por: Azad, Shorya Vardhan, et al.
Publicado: (2014)

Branch Retinal Vein Occlusion followed by Central Retinal Vein Occlusion
por: Moradian, Siamak, et al.
Publicado: (2009)

Efficacy and safety of widely used treatments for macular oedema secondary to retinal vein occlusion: a systematic review
por: Glanville, Julie, et al.
Publicado: (2014)

Long-term outcomes for patients treated for macular oedema secondary to retinal vein occlusion: a systematic review
por: Hunter, Alexandra, et al.
Publicado: (2022)

Ranibizumab as an adjunct to laser for macular edema secondary to branch retinal vein occlusion
por: Azad, Rajvardhan, et al.
Publicado: (2012)

Role of inflammation in previously untreated macular edema with branch retinal vein occlusion
por: Noma, Hidetaka, et al.
Publicado: (2014)

Branch retinal vein occlusion with sectoral cystoid macular edema in toxoplasmic chorioretinitis
por: Hafidi, Zouheir, et al.
Publicado: (2013)

Branch Retinal Vein Occlusion, Macular Ischemia, and Intravitreal Anti-VEGF Therapy
por: Bertelmann, Thomas, et al.
Publicado: (2017)

Comparison of Ranibizumab and Bevacizumab for Macular Edema Associated with Branch Retinal Vein Occlusion
por: Son, Bo Kwon, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_1hqi7gkkvaaomktlvrr15kuap0